Jonsson Comprehensive Cancer Center Clinical Trials
Sponsors / Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center is listed as the lead sponsor on 284 clinical trials registered with ClinicalTrials.gov. Across the portfolio, 47 are in recruitment, 34 are active non-recruiting, and 132 have reached completion. 29 trials have been terminated or withdrawn. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. Across the portfolio, planned enrollment totals 32,685 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.
284
Total Trials
47
Recruiting
34
Other Active
132
Completed
29
Terminated / Withdrawn
32,685
Total Enrollment
Termination reasons: Recruitment72% · Other14% · Funding7% · Safety7%
Recent Terminations
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified"slow accrual"
- Prostate Cancer"low accrual"
- Resectable Pancreatic Carcinoma"slow accrual"
- Anatomic Stage 0 Breast Cancer AJCC v8"enrollment"
- NCT04407546 Stopped Mar 2023Immunosuppression"enrollment"
- Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8"accrual"
- Biochemically Recurrent Prostate Carcinoma"slow recruitment"
- Castration-Resistant Prostate Carcinoma"slow accrual"
- Malignant Brain Neoplasm"insufficient accrual"
- NCT02888301 Stopped Apr 2018Malignant Neoplasm"slow accrual"
Active Trials (34 total)
- NCT03996850
- NCT04624256
- Prostate Carcinoma EARLY_PHASE1NCT04857502
- NCT06288113
- NCT02701153
- NCT04712851
- NCT04742608
- NCT05115760
- Prostate Carcinoma PHASE2NCT06216249
- Glioblastoma PHASE3NCT07461948
- Stage I Renal Cell Cancer PHASE1NCT04473781
- NCT01345851
- NCT02296229
- Lung Adenocarcinoma EARLY_PHASE1NCT07235280
- NCT06342908
- Advanced Malignant Solid Neoplasm PHASE1/PHASE2NCT03830918
- Prostate Carcinoma EARLY_PHASE1NCT05160597
- NCT06568016
- Bladder Carcinoma PHASE1NCT04459273
- NCT05775471